{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:42:17Z","timestamp":1791312137069,"version":"4.3.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T00:00:00Z","timestamp":1361232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T00:00:00Z","timestamp":1361232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1038\/mp.2013.19","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T05:23:28Z","timestamp":1361251408000},"page":"351-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":181,"title":["APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study"],"prefix":"10.1038","volume":"19","author":[{"given":"V K","family":"Ramanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S L","family":"Risacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Nho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T M","family":"Foroud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Hakonarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Huentelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P S","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R C","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R C","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C R","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Koeppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W J","family":"Jagust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M W","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J","family":"Saykin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,19]]},"reference":[{"key":"BFmp201319_CR1","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran E, Mercken M, De Strooper B . The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698\u2013712.","journal-title":"Nat Rev Drug Discov"},{"key":"BFmp201319_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362\u2013381.","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFmp201319_CR3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/archneur.63.5.665","volume":"63","author":"RC Petersen","year":"2006","unstructured":"Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006; 63: 665\u2013672.","journal-title":"Arch Neurol"},{"key":"BFmp201319_CR4","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","volume":"66","author":"DA Bennett","year":"2006","unstructured":"Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006; 66: 1837\u20131844.","journal-title":"Neurology"},{"key":"BFmp201319_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.tig.2009.12.004","volume":"26","author":"K Sleegers","year":"2010","unstructured":"Sleegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, Van Broeckhoven C . The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet 2010; 26: 84\u201393.","journal-title":"Trends Genet"},{"key":"BFmp201319_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280\u2013292.","journal-title":"Alzheimers Dement"},{"key":"BFmp201319_CR7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921\u2013923.","journal-title":"Science"},{"key":"BFmp201319_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"J Kim","year":"2009","unstructured":"Kim J, Basak JM, Holtzman DM . The role of apolipoprotein E in Alzheimer's disease. Neuron 2009; 63: 287\u2013303.","journal-title":"Neuron"},{"key":"BFmp201319_CR9","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1212\/WNL.0b013e3182662084","volume":"79","author":"AJ Furst","year":"2012","unstructured":"Furst AJ, Kerchner GA . From alois to amyvid: seeing Alzheimer disease. Neurology 2012; 79: 1628\u20131629.","journal-title":"Neurology"},{"key":"BFmp201319_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305: 275\u2013283.","journal-title":"JAMA"},{"key":"BFmp201319_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol 2012; 11: 669\u2013678.","journal-title":"Lancet Neurol"},{"key":"BFmp201319_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jalz.2010.03.007","volume":"6","author":"MW Weiner","year":"2010","unstructured":"Weiner MW, Aisen PS, Jack CR, Jagust WJ, Trojanowski JQ, Shaw L et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 2010; 6: 202\u2013211 e207.","journal-title":"Alzheimers Dement"},{"key":"BFmp201319_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jalz.2010.03.003","volume":"6","author":"WJ Jagust","year":"2010","unstructured":"Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA et al. The Alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimers Dement 2010; 6: 221\u2013229.","journal-title":"Alzheimers Dement"},{"key":"BFmp201319_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jalz.2010.03.013","volume":"6","author":"AJ Saykin","year":"2010","unstructured":"Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S et al. Alzheimer's disease neuroimaging initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement 2010; 6: 265\u2013273.","journal-title":"Alzheimers Dement"},{"key":"BFmp201319_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559\u2013575.","journal-title":"Am J Hum Genet"},{"key":"BFmp201319_CR16","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/ng.2354","volume":"44","author":"B Howie","year":"2012","unstructured":"Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR . Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012; 44: 955\u2013959.","journal-title":"Nat Genet"},{"key":"BFmp201319_CR17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/ng.2250","volume":"44","author":"JL Stein","year":"2012","unstructured":"Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, Winkler AM et al. Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet 2012; 44: 552\u2013561.","journal-title":"Nat Genet"},{"key":"BFmp201319_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/gepi.20303","volume":"32","author":"I Pe'er","year":"2008","unstructured":"Pe'er I, Yelensky R, Altshuler D, Daly MJ . Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet Epidemiol 2008; 32: 381\u2013385.","journal-title":"Genet Epidemiol"},{"key":"BFmp201319_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263\u2013265.","journal-title":"Bioinformatics"},{"key":"BFmp201319_CR20","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/bioinformatics\/btn564","volume":"24","author":"AD Johnson","year":"2008","unstructured":"Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI . SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008; 24: 2938\u20132939.","journal-title":"Bioinformatics"},{"key":"BFmp201319_CR21","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1056\/NEJMcp0910237","volume":"364","author":"RC Petersen","year":"2011","unstructured":"Petersen RC . Clinical practice. Mild cognitive impairment. N Engl J Med 2011; 364: 2227\u20132234.","journal-title":"N Engl J Med"},{"key":"BFmp201319_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/13546800903059829","volume":"14","author":"SG Potkin","year":"2009","unstructured":"Potkin SG, Turner JA, Guffanti G, Lakatos A, Torri F, Keator DB et al. Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: methodological considerations. Cogn Neuropsychiatry 2009; 14: 391\u2013418.","journal-title":"Cogn Neuropsychiatry"},{"key":"BFmp201319_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/mp.2010.8","volume":"15","author":"KS Kendler","year":"2010","unstructured":"Kendler KS, Neale MC . Endophenotype: a conceptual analysis. Mol Psychiatry 2010; 15: 789\u2013797.","journal-title":"Mol Psychiatry"},{"key":"BFmp201319_CR24","doi-asserted-by":"publisher","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"JM Castellano","year":"2011","unstructured":"Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 2011; 3: 89ra57.","journal-title":"Sci Transl Med"},{"key":"BFmp201319_CR25","first-page":"77sr71","volume":"3","author":"DM Holtzman","year":"2011","unstructured":"Holtzman DM, Morris JC, Goate AM . Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011; 3: 77sr71.","journal-title":"Sci Transl Med"},{"key":"BFmp201319_CR26","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1093\/brain\/aws127","volume":"135","author":"RM Koffie","year":"2012","unstructured":"Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D et al. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 2012; 135: 2155\u20132168.","journal-title":"Brain"},{"key":"BFmp201319_CR27","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1093\/hmg\/6.11.1933","volume":"6","author":"DJ Lehmann","year":"1997","unstructured":"Lehmann DJ, Johnston C, Smith AD . Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997; 6: 1933\u20131936.","journal-title":"Hum Mol Genet"},{"key":"BFmp201319_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrn1035","volume":"4","author":"S Darvesh","year":"2003","unstructured":"Darvesh S, Hopkins DA, Geula C . Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003; 4: 131\u2013138.","journal-title":"Nat Rev Neurosci"},{"key":"BFmp201319_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/ana.410420613","volume":"42","author":"AL Guillozet","year":"1997","unstructured":"Guillozet AL, Smiley JF, Mash DC, Mesulam MM . Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997; 42: 909\u2013918.","journal-title":"Ann Neurol"},{"key":"BFmp201319_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/FPC.0b013e3282f63f29","volume":"18","author":"R Lane","year":"2008","unstructured":"Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A et al. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics 2008; 18: 289\u2013298.","journal-title":"Pharmacogenet Genomics"},{"key":"BFmp201319_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.neulet.2008.07.023","volume":"442","author":"A Tasker","year":"2008","unstructured":"Tasker A, Ballard CG, Joachim C, Warden DR, Okello EJ, Perry RH et al. Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients. Neurosci Lett 2008; 442: 297\u2013299.","journal-title":"Neurosci Lett"},{"key":"BFmp201319_CR32","doi-asserted-by":"crossref","unstructured":"Lane RM, He Y . Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype. Alzheimers Dement, advance online publication, 10 March 2012; doi:10.1016\/j.jalz.2010.12.005.","DOI":"10.1016\/j.jalz.2010.12.005"},{"key":"BFmp201319_CR33","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000122962","volume":"25","author":"MR Farlow","year":"2008","unstructured":"Farlow MR, Miller ML, Pejovic V . Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 2008; 25: 408\u2013422.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"BFmp201319_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jalz.2006.02.001","volume":"2","author":"MN Sabbagh","year":"2006","unstructured":"Sabbagh MN, Farlow MR, Relkin N, Beach TG . Do cholinergic therapies have disease-modifying effects in Alzheimer\u2019s disease? Alzheimers Dement 2006; 2: 118\u2013125.","journal-title":"Alzheimers Dement"},{"key":"BFmp201319_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/NEN.0b013e31823cc7a6","volume":"71","author":"S Darvesh","year":"2012","unstructured":"Darvesh S, Cash MK, Reid GA, Martin E, Mitnitski A, Geula C . Butyrylcholinesterase is associated with beta-amyloid plaques in the transgenic APPSWE\/PSEN1dE9 mouse model of Alzheimer disease. J Neuropathol Exp Neurol 2012; 71: 2\u201314.","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFmp201319_CR36","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.neurobiolaging.2009.07.015","volume":"32","author":"T Darreh-Shori","year":"2011","unstructured":"Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C et al. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging 2011; 32: 2320, e2315-2320.e2332.","journal-title":"Neurobiol Aging"},{"key":"BFmp201319_CR37","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.neurobiolaging.2009.07.015","volume":"32","author":"T Darreh-Shori","year":"2011","unstructured":"Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H et al. The apolipoprotein E \u025b4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobio Aging 2011; 32: 1236\u20131248.","journal-title":"Neurobio Aging"},{"key":"BFmp201319_CR38","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.mehy.2009.01.050","volume":"73","author":"RM Lane","year":"2009","unstructured":"Lane RM, He Y . Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE \u025b4, and hyperhomocysteinemia in neurodegenerative dementias. MedHypotheses 2009; 73: 230\u2013250.","journal-title":"MedHypotheses"},{"key":"BFmp201319_CR39","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2169\/internalmedicine.46.0049","volume":"46","author":"T Iwasaki","year":"2007","unstructured":"Iwasaki T, Yoneda M, Nakajima A, Terauchi Y . Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med 2007; 46: 1633\u20131639.","journal-title":"Intern Med"},{"issue":"Suppl 1","key":"BFmp201319_CR40","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1186\/1471-2350-8-S1-S16","volume":"8","author":"JB Meigs","year":"2007","unstructured":"Meigs JB, Manning AK, Fox CS, Florez JC, Liu C, Cupples LA et al. Genome-wide association with diabetes-related traits in the Framingham Heart Study. BMC Med Genet 2007; 8 (Suppl 1): S16.","journal-title":"BMC Med Genet"},{"key":"BFmp201319_CR41","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1093\/hmg\/ddr375","volume":"20","author":"B Benyamin","year":"2011","unstructured":"Benyamin B, Middelberg RP, Lind PA, Valle AM, Gordon S, Nyholt DR et al. GWAS of butyrylcholinesterase activity identifies four novel loci, independent effects within BCHE and secondary associations with metabolic risk factors. Hum Mol Genet 2011; 20: 4504\u20134514.","journal-title":"Hum Mol Genet"},{"key":"BFmp201319_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrg2083","volume":"8","author":"P Kapranov","year":"2007","unstructured":"Kapranov P, Willingham AT, Gingeras TR . Genome-wide transcription and the implications for genomic organization. Nat Rev Genet 2007; 8: 413\u2013423.","journal-title":"Nat Rev Genet"},{"key":"BFmp201319_CR43","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1523\/JNEUROSCI.23-07-02665.2003","volume":"23","author":"ME Bamberger","year":"2003","unstructured":"Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE . A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 2003; 23: 2665\u20132674.","journal-title":"J Neurosci"},{"key":"BFmp201319_CR44","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1172\/JCI57256","volume":"122","author":"TR Bomfim","year":"2012","unstructured":"Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers. J Clin Invest 2012; 122: 1339\u20131353.","journal-title":"J Clin Invest"},{"key":"BFmp201319_CR45","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/brain\/awn016","volume":"131","author":"MD Ikonomovic","year":"2008","unstructured":"Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630\u20131645.","journal-title":"Brain"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/mp201319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/mp201319","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/mp201319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T22:40:58Z","timestamp":1648766458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/mp201319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,19]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["BFmp201319"],"URL":"https:\/\/doi.org\/10.1038\/mp.2013.19","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,19]]},"assertion":[{"value":"10 October 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Jagust has served as a consultant to TauRx Therapeutics Ltd, GE Healthcare, Siemens, Synarc and Janssen Alzheimer Immunotherapy. Dr Weiner has served on scientific advisory boards for Eli Lilly, Araclon, Institut Catala de Neurociencies Aplicades, the Gulf War Veterans Illnesses Advisory Committee, Biogen Idec and Pfizer; has served as a consultant to Astra Zeneca, Araclon, Medivation\/Pfizer, Ipsen, TauRx Therapeutics Ltd, Bayer Healthcare, Biogen Idec, Exonhit Therapeutics, Servier, Synarc, Janssen, Harvard University and KLJ Associates; has received funding for travel from NeuroVigil Inc, CHRU H\u00f4pital Roger Salengro, Siemens, AstraZeneca, Geneva University Hospitals, Eli Lilly, Paris University, Institut Catala de Neurociencies Aplicades, University of New Mexico School of Medicine, Ipsen, Clinical Trials on Alzheimer\u2019s Disease, the AD\/PD Meeting, Paul Sabatier University, Novartis, Tohoku University, Fundacio ACE and Travel eDreams, Inc; has received honoraria from NeuroVigil, Inc, Institut Catala de Neurociencies Aplicades, PMDA\/Japanese Ministry of Health, Labor and Welfare, Tohoku University and the Alzheimer\u2019s Drug Discovery Foundation; has received research support from Merck and Avid; and has stock options for Synarc and Elan. Dr Saykin has received investigator-initiated research funding from Welch Allyn and Siemens Healthcare, and has served as a consultant or advisory board member for Siemens Healthcare and Eli Lilly. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}